MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 10, 2015, Pages 548-555

  Tao, Liu ^a   Li, Zuo ^b   Lin, Li ^a   Lei, Yin ^a   Hongyuan, Yu ^a   Hongwei, Jing ^a   Yang, Liu ^a   Chuize, Kong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; STROMELYSIN; MMP1 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN;

ARTICLE; ASIAN; BLADDER CANCER; CANCER RISK; DNA POLYMORPHISM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFORMATION RETRIEVAL; KIDNEY CARCINOMA; MEDLINE; META ANALYSIS (TOPIC); POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UROGENITAL TRACT CANCER; WANFANG DATABASE; BLADDER TUMOR; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; ODDS RATIO; RISK FACTOR;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84943569761     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2015.0123     Document Type: Article

References (44)

1. Albayrak S, Canguven O, Goktas x C, et al. (2007) Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int 79:312-315.
2. Awakura Y, Ito N, Nakamura E, et al. (2006) Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett 241:59-63.
3. Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317-1323.
4. Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830.
5. Chakraborti S, Mandal M, Das S, et al. (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285.
6. Decock J, Paridaens R, Ye S (2008) Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet 73:197-211.
7. DerSimonian R, Laird N (1986) Meta-Analysis in clinical trials. Control Clin Trials 7:177-188.
8. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
9. Forget MA, Desrosiers RR, Beliveau R (1999) Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465-480.
10. Gum R, Lengyel E, Juarez J, et al. (1996) Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogenactivated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271:10672-10680.
11. Hayashino Y, Noguchi, Y Fukui, T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15:235-243.
12. Hirata H, Okayama N, Naito K, et al. (2004) Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis 25:2379-2384.
13. Jormsjo S, Whatling C, Walter DH, et al. (2001) Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 21:1834-1839.
14. Kader AK, Shao L, Dinney CP, et al. (2006) Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644-11648.
15. Liu D, Duan W, Guo H, et al. (2011) Meta-Analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. Int J Colorectal Dis 26:1099-1105.
16. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696-1701.
17. Mannello F, Luchetti F, Falcieri E, Papa S (2005) Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10:19-24.
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
19. Pereira AC, Dias do Carmo E, Dias da Silva MA, et al. (2012) Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent 4:e297-301.
20. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850-860.
21. Piccoli MF, Figueira M, Andreoni C, et al. (2007) Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma. Int Braz J Urol 33:622-629.
22. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in thehuman matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549-7558.
23. Rutter JL, Mitchell TI, Buttice G, et al. (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58:5321-5325.
24. Sherry ST, Ward M, Sirotkin K (1999) dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 9:677-679.
25. Srivastava P, Gangwar R, Kapoor R, Mittal RD (2010a) Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers 29:37-46.
26. Srivastava P, Kapoor R, Mittal RD (2013a) Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol 31:247-254.
27. Srivastava P, Kapoor R, Mittal RD (2013b) Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Gene 530:273-277.
28. Srivastava P, Mandhani A, Kapoor R, Mittal RD (2010b) Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol 17:3068-3075.
29. Stamenkovic I. (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-433.
30. Tasci AI, Tugcu V, Ozbek E, et al. (2008) A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int 101:503-507.
31. Tsuchiya N, Narita S, Kumazawa T, et al. (2009) Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol Rep 22:493-499.
32. VanSaun MN, Matrisian LM (2006) Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 78:69-79.
33. Wang J, Cai Y (2012) Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-Analysis. Tumour Biol 33:1819-1828.
34. Wieczorek E, Reszka E, Gromadzinska J, et al. (2012) Genetic polymorphism of matrix metalloproteinases in breast cancer. Neoplasma 59:237-247.
35. Wieczorek E, Reszka E, Jablonowski Z, et al. (2013) Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int 112:1207-1214.
36. Wieczorek E, Reszka E, Wasowicz W, et al. (2014) MMP7 and MMP8 genetic polymorphisms in bladder cancer patients. Cent European J Urol 66:405-410.
37. Wilson CL, Matrisian LM (1996) Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28:123-136.
38. Yang TF, Guo L, Wang Q (2014) Meta-Analysis of associations between four polymorphisms in the matrix metalloproteinases gene and gastric cancer risk. Asian Pac J Cancer Prev 15: 1263-1267.
39. Yaykasxli KO, Kayikci MA, Yamak N, et al. (2014) Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci 44:839-843.
40. Yu C, Zhou Y, Miao X, et al. (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622-7628.
41. Zhang B, Ye S, Herrmann SM, et al. (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99:1788-1794.
42. Zhang C, Li C, Zhu M, et al. (2013) Meta-Analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One 8:e62023.
43. Zhang X, Jin G, Li J, et al. (2015) Association between four MMP-9 polymorphisms and breast cancer risk: a metaanalysis. Med Sci Monit 21:1115-1123.
44. Zhong A, Ye ZQ (2005) MMP-2 and MMP-9 expressions in tumor tissues and two functional single nucleotide polymorphisms associated with transitional cell carcinoma of bladder. Huazhong University of Science and Technology [Doctoral Dissertation].